BEIJING, March 30 -- China is soliciting public review of a set of new rules on stem-cell research.

According to a document published by the National Health and Family Planning Commission and China Food and Drug Administration, stem-cell clinical trials refer to transplantation of stem-cells for the purpose of disease prevention or research.

The document proposes that all clinical records of stem-cell providers and subjects should be kept for at lease 30 years.

Subjects should be observed after clinical trials to assess long-term safety and effectiveness of the research, said the document.

The document also proposed that stem-cell researchers should help subjects understand the goal of research as well as its risks. It also said subjects should be insured and research should stop once adverse reactions emerge.